By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.

Key Statistics

Ownership: Public

Web Site: Alexion Pharmaceuticals Inc.
Employees: 1,500
Symbol: ALXN



Company News
Alexion Pharmaceuticals Inc. (ALXN) Reports Fourth Quarter And Full Year 2014 Results And Provides Financial Guidance For 2015 1/29/2015 11:11:04 AM
Alexion Pharmaceuticals Inc. (ALXN) Turns to Profit in Q4; Appoints New CEO 1/29/2015 6:13:53 AM
Alexion Pharmaceuticals Inc. (ALXN) To Report Fourth Quarter And Full Year 2014 Results On Thursday, January 29, 2015 1/21/2015 12:03:41 PM
Alexion Pharmaceuticals Inc. (ALXN) Release: Researchers To Present New Data On Asfotase Alfa In Children With Hypophosphatasia (HPP) As Well As Burden Of Disease Data In Adults With HPP At ENDO 2015 Annual Meeting 1/21/2015 11:33:36 AM
Alexion Pharmaceuticals Inc. (ALXN) Provides Update On Phase 2 Clinical Trial With Eculizumab In Antibody Mediated Rejection (AMR) In Living-Donor Kidney Transplant Recipients 1/8/2015 7:09:54 AM
Alexion Pharmaceuticals Inc. (ALXN) To Present At The J.P. Morgan 33rd Annual Healthcare Conference 1/5/2015 9:39:02 AM
Alexion Pharmaceuticals Inc. (ALXN) Completes Rolling BLA Submission To U.S. FDA For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 12/30/2014 8:16:40 AM
X-Chem And Alexion Pharmaceuticals Inc. (ALXN) Collaborate To Discover Novel Therapeutic Candidates To Treat Patients With Severe And Ultra-Rare Disorders 12/11/2014 8:30:20 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: Soliris® (Eculizumab) Granted Orphan Drug Designation In Japan For The Treatment Of Patients With Myasthenia Gravis 12/11/2014 7:41:25 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: New Data Presented At American Society of Hematology Annual Meeting Enhance Clinical Knowledge Of aHUS And PNH And Underscore The Effectiveness Of Soliris® (Eculizumab) Treatment 12/9/2014 12:06:35 PM